HB1256 amends the Illinois Workers’ Compensation Act to create specific payment rules for custom compound medications used in workers’ compensation claims. The bill defines a “custom compound medication,” then requires that payment for compounds longer than a one-time 7-day supply be approved only if the compound meets several conditions, including the absence of a commercially available equivalent, no appropriate FDA-approved alternative, use of FDA-approved active ingredients, no safety withdrawal from the market, and clinical appropriateness demonstrated by the prescriber. It also limits initial coverage to a one-time 7-day supply unless the employer preauthorizes a longer prescription.
The bill changes how compound drugs are priced for reimbursement. Charges must be based on the specific amount of each ingredient and its original manufacturer’s National Drug Code, with repackaged drugs tied back to the underlying manufacturer’s NDC and ingredients without NDCs not billable. A single dispensing fee would be allowed for the compound, set by the Commission based on actual preparation and dispensing costs. The bill also states that the employer must preauthorize any compound prescription beyond 7 days, while a 7-day supply must be covered if the compound otherwise meets the statutory requirements. The measure takes effect immediately.
Impact
HB1256 would narrow and standardize reimbursement for custom compound medications under the Workers’ Compensation Act, affecting employers, workers’ compensation insurers, pharmacies, prescribers, and injured employees. It would add a new layer of medical-necessity and formulary-like review for longer compound prescriptions, and it would tie reimbursement to National Drug Code-based ingredient pricing rather than broader billed charges. In practice, the bill would likely reduce payment disputes over compounded drugs, limit billing for non-NDC ingredients, and constrain the duration of initial compound prescriptions unless the employer authorizes more.
Sentiment
No committee transcripts or recorded votes were provided, so there is no direct public record here of debate or roll-call sentiment. Based on the bill text, the measure appears designed to control workers’ compensation drug costs and curb potentially excessive compound medication billing, which suggests support from cost-containment interests and likely resistance from compound pharmacies, some providers, or claimant advocates concerned about access and prior authorization barriers. The overall tone of the proposal is regulatory and restrictive rather than expansive.
Contention
The main points of contention are likely to be whether the bill unduly restricts access to medically necessary compounded medications and whether the new approval standards are too burdensome for injured workers and prescribers. Opponents may object to the 7-day default limit, employer preauthorization requirement, and the exclusion of ingredients without National Drug Codes, arguing these provisions could delay treatment or deny individualized care. Supporters are likely to argue that the bill prevents overbilling, discourages off-label or unsupported compound use, and aligns reimbursement with objective pricing data. The most affected parties would be injured employees seeking compounded medications, employers and insurers paying workers’ compensation claims, and pharmacies that dispense compounded prescriptions.
Patient Access to Urgent-Use Pharmacy Compounding Act of 2023 This bill relaxes certain requirements for compounding drugs that are facing shortages. Drug compounding is the process of mixing or otherwise altering drugs to create a medication. Currently, the Food and Drug Administration (FDA) allows for drug compounding subject to certain requirements. Generally, a licensed pharmacist or physician not registered with the FDA may only compound drugs in limited quantities for prescriptions for a specific individual patient. On the other hand, an FDA-registered outsourcing facility may compound drugs in bulk for use in medical facilities but is subject to additional requirements. This bill allows a compounder not registered with the FDA to compound drugs in limited quantities for an urgent medical need not involving a specific patient if, among other requirements (1) the prescriber certifies that the prescriber is unable, despite reasonable attempts, to obtain certain related drugs with the same active ingredient and route of administration; (2) the compounded drug meets certain labeling requirements, including an indication that the compounded drug is provided only for urgent administration to a patient; and (3) the compounder requests and maintains certain records about patients receiving the compounded drug. Furthermore, a restriction against an unregistered compounder regularly compounding (or compounding inordinate amounts of) what is essentially a copy of a commercially available drug shall not apply if the drug is on a shortage list maintained by the FDA or the American Society of Hospital Pharmacists.